Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells
Gilead’s $4.9 billion buyout of Forty Seven, announced in early March, landed in a different era before the pandemic consumed biopharma news. But even amid all the buzz around its potential Covid-19 treatment remdesivir, CEO Daniel O’Day is still making clear that oncology is where he wants to take the company.
His latest deal is a research collaboration involving a low-profile player headquartered in Melbourne — so stealthy that the upfront payment and total value are all still under wraps. What Gilead did reveal, however, is an interest in oNKo-innate’s expertise in natural killer cells as a new frontier of immuno-oncology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.